However, when it comes to the effects on T cells, it has been observed that targeting MEK produces a decrease in T-cell proliferation [95,97] in normal human lymphocytes and in CD8/CD4/FOXP3 T-cell proliferation [98] in breast cancer. Here, MAP2K7 is linked to breast carcinoma.